Gerry Northam presents a programme looking at controversy surrounding perceived results of drugs trials on AZT (marketed as Retrovir) since early 1980's, which have been interpreted by drug companies to show benefits of taking drugs early.
Gerry Northam presents a programme looking at controversy surrounding perceived results of drugs trials on AZT (marketed as Retrovir) since early 1980's, which have been interpreted by drug companies to show benefits of taking drugs early.